CRO Precontract Audits - Applied Clinical Trials

ADVERTISEMENT

pagepush
See our 2009 Buyers Guide Digital Edition.
Find Pharma Search Engine
CRO Precontract Audits

Source: Applied Clinical Trials




Since clinical trials and/or noninterventional studies (NIS) represent major investments by pharmaceutical companies and the choice of a CRO is a crucial success factor for the project, it should be common practice to perform precontract audits at those CROs in question with which no cooperation is established yet.1

In general, these audits are performed by experienced quality management (QM) employees of the sponsor, who do not always have a profound background in data management (DM), biostatistics/statistical programming (BIO) or medical writing (MW). Up to now, these fields, which are only a part of the tasks to be subcontracted, were to some extent neglected in such audits.



This article focuses on aspects to be checked with regard to data management facilities, biostatistics, and medical writing know-how of the CRO and may serve as a guide for audit activities in these fields.

Questions for the CRO

A crucial question to begin with is: Has the CRO developed and kept up to date its own standard operating procedures (SOPs) with regard to DM, BIO, and MW workflows and corresponding interfaces between these functions, and is it willing to provide these SOPs so that they can be checked by the sponsor. The CRO should also be willing to perform the subcontracted activities according to the sponsor's own SOPs.

In order to assess capabilities and free capacity, the CRO should provide numbers of clinical trials by development phases it is currently working on and has worked on in the last 12 months (plus noninterventional studies if applicable).


Figure 1. Important questions to ask a CRO when inquiring about the amount in which they use third parties.
The CRO should give concise figures to quantify which parts of their activities are subcontracted to third parties—for example, other CROs or freelancers in the fields of DM, BIO, statistical programming, and MW (see Figure 1).

The CRO should specify the number and qualification of employees in the different functions. Curricula vitae as well as job descriptions should be available for all coworkers and should be up to date. An important issue is continuing training of coworkers, and this should be documented by training certificates and/or training logs.

The sponsor should also get an organization chart and information should be given by the CRO regarding fluctuation of employees (e.g., percentage of employees replaced) in the different functions during the last two years.


ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All comments submitted are subject to review, and may be delayed before posting. We reserve the right not to post comments.

ADVERTISEMENT

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
93%
Borrow lightly from EMA's pathway program?
0%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here